{"id":798801,"date":"2025-01-08T07:08:30","date_gmt":"2025-01-08T12:08:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/"},"modified":"2025-01-08T07:08:30","modified_gmt":"2025-01-08T12:08:30","slug":"ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/","title":{"rendered":"Ocular Therapeutix\u2122 to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Company presentation scheduled on Monday, January 13th at 5:15 PM PT<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Ocular to provide enrollment update for SOL-R, Ocular\u2019s second registrational trial of AXPAXLI\u2122 in wet AMD, future opportunities for AXPAXLI, and a general corporate overview<\/em>\n      <\/p>\n<p>BEDFORD, Mass., Jan.  08, 2025  (GLOBE NEWSWIRE) &#8212; \u00a0Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d, the \u201cCompany\u201d), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company will present its strategic outlook for 2025 at the 43<sup>rd<\/sup> Annual J.P. Morgan Healthcare Conference on January 13, 2025 at 5:15 PM PT in San Francisco, CA.<\/p>\n<p>Pravin U. Dugel, MD, Ocular\u2019s Executive Chairman, President and CEO, will provide an update regarding the enrollment status of SOL-R, the Company\u2019s second registrational trial of AXPAXLI\u2122 for the treatment of wet age-related macular degeneration (wet AMD), future opportunities for AXPAXLI, and a general corporate overview.<\/p>\n<p>\n        <strong>43<\/strong><br \/>\n        <sup><br \/>\n          <strong>rd<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual J.P. Morgan Healthcare Conference Presentation Details<\/strong><br \/>\n        <br \/>Presentation Date: Monday, January 13, 2025<br \/>Presentation Time: 5:15 PM PT <br \/>Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO<br \/>Location: San Francisco, CA<\/p>\n<p>The live presentation can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page.<\/p>\n<p>\n        <strong>About\u00a0Ocular\u00a0Therapeutix,\u00a0Inc.<\/strong><br \/>\n        <br \/>Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI\u2122 (axitinib intravitreal injection, also known as OTX-TKI), Ocular\u2019s product candidate for retinal disease, is based on its ELUTYX\u2122 proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).<\/p>\n<p>Ocular\u2019s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA\u00ae, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA\u2122 (travoprost intracameral injection or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.<\/p>\n<p>Follow the Company on its website, LinkedIn, or X.<\/p>\n<p>The Ocular Therapeutix logo and DEXTENZA\u00ae are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI\u2122, PAXTRAVA\u2122, ELUTYX\u2122, and Ocular Therapeutix\u2122 are trademarks of Ocular Therapeutix, Inc.<\/p>\n<p>\n        <strong>Investors &amp; Media<\/strong><br \/>\n        <br \/>Ocular Therapeutix, Inc.<br \/>Bill Slattery<br \/>Vice President, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Kx8T4OpitlJ2ueYgRwsDZpkOyYcL_HZaYziw7FSoLiL_b-CeVQ8xR8dQTeGrG4nvb38Eck7TLPOZQY0TGojxRFSoWRro2qLdTQqxAtkLyFU=\" rel=\"nofollow\" target=\"_blank\">bslattery@ocutx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODM5MiM2NjgzODU3IzIwMTEwNTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YWIxYzlhNjktMWQxOS00ZTUwLWFkYjQtMDA1NzlmOGRhOTYzLTEwMjI2Mjk=\/tiny\/Ocular-Therapeutix-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company presentation scheduled on Monday, January 13th at 5:15 PM PT Ocular to provide enrollment update for SOL-R, Ocular\u2019s second registrational trial of AXPAXLI\u2122 in wet AMD, future opportunities for AXPAXLI, and a general corporate overview BEDFORD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) &#8212; \u00a0Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d, the \u201cCompany\u201d), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company will present its strategic outlook for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 at 5:15 PM PT in San Francisco, CA. Pravin U. Dugel, MD, Ocular\u2019s Executive Chairman, President and CEO, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ocular Therapeutix\u2122 to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-798801","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ocular Therapeutix\u2122 to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocular Therapeutix\u2122 to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company presentation scheduled on Monday, January 13th at 5:15 PM PT Ocular to provide enrollment update for SOL-R, Ocular\u2019s second registrational trial of AXPAXLI\u2122 in wet AMD, future opportunities for AXPAXLI, and a general corporate overview BEDFORD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) &#8212; \u00a0Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d, the \u201cCompany\u201d), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company will present its strategic outlook for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 at 5:15 PM PT in San Francisco, CA. Pravin U. Dugel, MD, Ocular\u2019s Executive Chairman, President and CEO, &hellip; Continue reading &quot;Ocular Therapeutix\u2122 to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-08T12:08:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODM5MiM2NjgzODU3IzIwMTEwNTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ocular Therapeutix\u2122 to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation\",\"datePublished\":\"2025-01-08T12:08:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\\\/\"},\"wordCount\":405,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODM5MiM2NjgzODU3IzIwMTEwNTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\\\/\",\"name\":\"Ocular Therapeutix\u2122 to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODM5MiM2NjgzODU3IzIwMTEwNTY=\",\"datePublished\":\"2025-01-08T12:08:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODM5MiM2NjgzODU3IzIwMTEwNTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyODM5MiM2NjgzODU3IzIwMTEwNTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocular Therapeutix\u2122 to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocular Therapeutix\u2122 to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/","og_locale":"en_US","og_type":"article","og_title":"Ocular Therapeutix\u2122 to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation - Market Newsdesk","og_description":"Company presentation scheduled on Monday, January 13th at 5:15 PM PT Ocular to provide enrollment update for SOL-R, Ocular\u2019s second registrational trial of AXPAXLI\u2122 in wet AMD, future opportunities for AXPAXLI, and a general corporate overview BEDFORD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) &#8212; \u00a0Ocular Therapeutix, Inc. (NASDAQ: OCUL, \u201cOcular\u201d, the \u201cCompany\u201d), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company will present its strategic outlook for 2025 at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 at 5:15 PM PT in San Francisco, CA. Pravin U. Dugel, MD, Ocular\u2019s Executive Chairman, President and CEO, &hellip; Continue reading \"Ocular Therapeutix\u2122 to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-08T12:08:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODM5MiM2NjgzODU3IzIwMTEwNTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ocular Therapeutix\u2122 to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation","datePublished":"2025-01-08T12:08:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/"},"wordCount":405,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODM5MiM2NjgzODU3IzIwMTEwNTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/","name":"Ocular Therapeutix\u2122 to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODM5MiM2NjgzODU3IzIwMTEwNTY=","datePublished":"2025-01-08T12:08:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODM5MiM2NjgzODU3IzIwMTEwNTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyODM5MiM2NjgzODU3IzIwMTEwNTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-provide-corporate-update-during-43rd-annual-j-p-morgan-healthcare-conference-presentation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ocular Therapeutix\u2122 to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798801","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=798801"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798801\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=798801"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=798801"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=798801"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}